Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients

Sponsor
Majianhua
Study ID
NCT03982238
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Insulin — DRUG
    Continuous subcutaneous insulin infusion therapy for 1 month
  • Metformin — DRUG
    Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month
  • Dapagliflozin — DRUG
    Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month

Study Details

The study will assess the total testosterone and sex hormone-binding globulin levels in men with type 2 diabetes before and after continuous subcutaneous insulin infusion and hypoglycemic drugs treatment.

Key Dates

Start date
Jun 15, 2019
Status verified
Jun 2019
Primary completion
Nov 15, 2019
Completion
Dec 31, 2019

Study Design

Enrollment
74 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Control group
    continuous subcutaneous insulin infusion therapy
  • Experimental: Metformin
    metformin therapy
  • Experimental: Dapagliflozin
    Dapagliflozin

Primary Outcome Measure

total testosterone levels [ Time Frame: 1 month ]

Related Studies